WARNINGMIXING OR WITHDRAWAL CAN BE DANGEROUS
Ordinary doses in combination with other depressants can fatally stop breathing. After prolonged dependency, stopping suddenly can also cause seizures or delirium; seek medical help.
Oxazepam
Oxazepam is an intermediate-acting benzodiazepine1 prescribed for the treatment of anxiety disorders2, panic disorders, alcohol withdrawalcitation needed, and insomnia1. It is characterized by relatively low potency compared to other benzodiazepines, a slow onset of action, and a simple metabolic profile that makes it less susceptible to variability based on age or liver functioncitation needed. It is notably an active metabolite of both diazepam and temazepam. Higher doses may produce amnesia and lowered inhibitions.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
The oxazepam experience is dominated by calm, physical relaxation, and relief from anxiety, with essentially no sensory alteration. As a slow-onset, relatively mild benzodiazepine, its effects build gradually and center on sedation and a dampening of emotional intensity rather than any recreational high. At higher doses, inhibitions loosen and memory of the period after ingestion becomes patchy or absent.
Physical
Muscle relaxation and a heavy, sedated body feeling are the primary physical effects, accompanied by suppression of spasms and seizures. Fatigue, motor impairment, muscle weakness, headaches, and, at high doses, slowed breathing have been reported.
Cognitive
The headspace is calm and emotionally muted, with slowed thinking, reduced anxiety, and lowered inhibitions. Confusion and anterograde amnesia become increasingly likely as the dose rises.
Suppressions
Cognitive effects are broadly suppressive, reflecting reduced signaling between neurons across the central nervous system.
Pharmacology
Pharmacodynamics
Oxazepam acts as a positive allosteric modulator of GABA-A receptors, binding at the benzodiazepine site located at the interface between the alpha and gamma subunits of the receptor. This binding potentiates the inhibitory effects of endogenous GABA in the central nervous system.3 Oxazepam also acts as an agonist at the translocator protein and has been shown to suppress cortisol levels.citation needed
Pharmacokinetics
Oxazepam is metabolized through a relatively simple pathway involving direct glucuronidation, without requiring hepatic oxidation.citation needed The S-enantiomer is glucuronidated by UGT2B15, while the R-enantiomer is processed by UGT2B7 and UGT1A9, yielding a single major inactive glucuronide conjugate. Oxazepam itself is an active metabolite formed during the breakdown of diazepam, nordazepam, and temazepam, and it undergoes very little additional biotransformation following absorption. The mean elimination half-life is approximately 8.2 hours, with a reported range of 6 to 9 hours.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Benzodiazepines, Other GABAergic depressants
Harm Potential
Addiction & Dependence
Psychological
ModerateOxazepam has documented abuse potential as a benzodiazepine, though its slow absorption and onset of action result in relatively lower abuse potential compared to faster-acting benzodiazepines such as temazepam, flunitrazepam, or triazolam.citation needed Misuse, defined as taking the drug to achieve a high or continuing use against medical advice, has been documented.
Physical
HighPhysical dependence develops with regular use, even at standard dosages and after relatively short-term use.citation needed Withdrawal symptoms are similar to those seen with alcohol and barbiturate withdrawal, including abdominal and muscle cramps, seizures, depression, insomnia, sweating, tremors, nausea, vomiting, and potentially hallucinations. Withdrawal should be medically supervised with gradual dose reduction.
Toxicity
Respiratory depression may occur in overdose or when combined with other CNS depressants;4 at typical doses, significant respiratory effects are uncommon except in patients with pre-existing pulmonary conditions such as COPD or limited pulmonary reserve.
Hypotension may rarely occur during use; cardiovascular toxicity is occasionally observed in overdose situations.
Psychosis Risk
Paradoxical reactions including excitement, confusion, aggression, outbursts of anger, and restlessness may occur as side effects.citation needed Hallucinations have been reported primarily as a withdrawal symptom rather than during active use.
Seizure Risk
Oxazepam itself has anticonvulsant properties as a benzodiazepine. However, seizures are a significant risk during withdrawal, particularly after prolonged use or abrupt discontinuation.4 Some benzodiazepines may trigger seizures in individuals with epilepsy. Flumazenil administration in long-term users may also precipitate seizures.4
History & Culture
Oxazepam was patented in 1962 and received approval for medical use in 1964. The compound became one of the most commonly prescribed benzodiazepines in multiple countries during the late 20th century.…
Legality
International
1961 Single Convention: oxazepam is not scheduled.
1971 Convention on Psychotropic Substances: Schedule IV.
1988 Convention: oxazepam is not listed in precursor Tables I or II.
By Country
References
Source Pages
Citations
- Ravneet Singh, Preeti Patel, & Sara Abdijadid. (2025). Oxazepam. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK544349/12
- OXAZEPAM capsule, gelatin coated — DailyMed (FDA Label, setid a0d5a4c1). DailyMed / NLM (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43123
- Engin E. (January 12, 2023). GABAA receptor subtypes and benzodiazepine use, misuse, and abuse. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.10609491
- Oxazepam Capsules – Prescribing Information (DailyMed setid 67f821fa). U.S. National Library of Medicine / DailyMed (n.d.). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67f821fa-5663-4d69-82c9-5ee13a09f324123
- Wood, Jennifer M.. (12 April 2017). 11 Words That Will Win You Any Game of Scrabble. Mental Floss. https://www.mentalfloss.com/article/50090/10-words-will-win-you-any-game-scrabble1
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, Schedule 4. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/latest/text1
- Government of Canada. (n.d.). Controlled Drugs and Substances Act — Schedule IV. Justice Laws Website. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/section-sched95660.html1
- Controlled Drugs and Substances Act, Schedule IV; Benzodiazepines and Other Targeted Substances Regulations (SOR/2000-217), Schedule 1. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/regulations/SOR-2000-217/section-sched661316.html1
- Controlled Drugs and Substances Act, Schedule IV; Benzodiazepines and Other Targeted Substances Regulations (SOR/2000-217), Schedule 1. laws-lois.justice.gc.ca (n.d.). https://laws-lois.justice.gc.ca/eng/regulations/SOR-2000-217/index.html1
- Betäubungsmittelgesetz, Anlage III; Betäubungsmittel-Verschreibungsverordnung. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html1
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
19 August 2026
Lyrea · Changed a word in Dosage & Duration › Routes 1 › Stages › Onset
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Oxazepam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.